Pharma - HealthQuill

The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died due to an infection, according to a company statement.

FDA halts Rocket’s Danon disease mid-stage therapy as patient dies

HQ Team May 28, 2025: The US drug regulator halted Rocket Pharmaceuticals Inc.’s investigational gene therapy for Danon disease after a patient died.

by HealthQuill
May 28, 2025
0 Comments

Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor that may cure chronic pain without using opioids.

Drugs Health Pharma

Eli Lilly to buy SiteOne to grab test inhibitor to treat chronic pain

HQ Team May 28, 2025: Eli Lilly and Company will acquire SiteOne Therapeutics, Inc. for $1 billion to get access to an inhibitor.

by HealthQuill
May 28, 2025
0 Comments

Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

by HealthQuill
May 24, 2025
0 Comments

Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases, for $470 million.

Drugs Health Pharma

France’s Sanofi SA to acquire US-based Vigil Neuroscience for $470 million

HQ Team May 22, 2025: Sanofi SA will acquire Vigil Neuroscience, Inc., a publicly traded clinical-stage biotechnology company focused on developing novel therapies.

by HealthQuill
May 22, 2025
0 Comments

Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total of $170 million.

Drugs Health Pharma

Governments, philanthropic partners pledge $170 million to WHO

HQ Team May 21, 2025: Long-standing allies and new contributors have stepped up funding to the cash-strapped World Health Organization with a total.

by HealthQuill
May 21, 2025
0 Comments

The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating evidence to support abbreviated new drug application approvals.

Drugs Health Pharma

FDA draws up new product guidance for developing generic drugs

HQ Team May 21, 2025: The Food and Drug Administration has come out with new product-specific guidances for developing generic drugs and generating.

by HealthQuill
May 21, 2025
0 Comments

Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe Holding, for $256 million.

Drugs Medical Pharma

Regeneron to buy bankrupt 23andMe Holding assets for $256 million

HQ Team May 20, 2025: Regeneron Pharmaceuticals, Inc. plans to buy most of the assets of the bankrupt genetics and biotechnology company, 23andMe.

by HealthQuill
May 20, 2025
0 Comments

Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and commercialise an experimental cancer drug.

Drugs Health Pharma

Pfizer signs $6 billion licensing deal with China’s 3SBio for cancer drug

HQ Team May 20, 2025: Pfizer Inc. has signed a licensing deal worth about $6 billion with China’s 3SBio to develop, manufacture and.

by HealthQuill
May 20, 2025
0 Comments

The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis.

Drugs Health Pharma

UK clears Janssen-Cilag’s drug for Crohn’s disease, ulcerative colitis

HQ Team May 19, 2025: The UK’s Medicines and Healthcare products Regulatory Agency has approved Janssen-Cilag Limited’s guselkumab (Tremfya) to treat Crohn’s disease.